Studies how pelvic bowel cancer returns after first treatment
Tests a new scan-based staging system in people with recurrent colorectal cancer in the pelvis.
Plain-language title generated from the registry record
Registry title: Beyond TME Origins
Key facts
- Where
- Oslo, NorwaySee the site
Where in Norway
- Oslo University HospitalOslo, NorwayTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Imperial College London
- Trial code
- NCT02292641
- Record updated
- 17 October 2024
- Original description
All patients with recurrent colorectal cancer in the pelvis are eligible. The original primary tumour staging scans and resected surgical specimen needs to be available. Patients' recurrence will be staged using our proposed MRI classification. We will be assessing the original primary staging scans and histopathology to learn about risk factors for recurrence. We will record treatment for the recurrence, and patients will be followed up for three years.Read full original descriptionShow less
Investigating the Origins of Pelvic Recurrence in Colorectal Cancer
All patients with recurrent colorectal cancer in the pelvis are eligible. The original primary tumour staging scans and resected surgical specimen needs to be available. Patients' recurrence will be staged using our proposed MRI classification. We will be assessing the original primary staging scans and histopathology to learn about risk factors for recurrence. We will record treatment for the recurrence, and patients will be followed up for three years.
Inclusion: Had a primary colorectal adenocarcinoma proven by biopsy taken as part of routine clinical practice; Has a confirmed diagnosis of recurrent pelvic colorectal cancer; Has previously completed surgical treatment of primary adenocarcinoma of the colon, sigmoid colon or rectum; Are able to undergo high resolution MRI for staging prior to treatment decisions; Have provided written informed consent to participate in the study; Be aged 16 years or over.
Exclusion: Original preoperative, surgical and adjuvant treatment has not been documented or is unavailable; Have irresectable extra-pelvic metastatic disease; Original baseline staging and preoperative restaging scans (MR for rectal and sigmoid cancers and/or CT for colon and sigmoid cancers) are unavailable.